MIA3 in Coronary Artery Disease (CAD): An In-Depth Review of Its Role in Vascular Smooth Muscle Cell (VSMC)

Yousuf Tahir Ali1,2, Aarthi Ravindran3, Luis Eichelmann4,5,6

  • 1Department of Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

IUBMB Life
|November 11, 2025
PubMed

Insights

The melanoma inhibitory activity protein-3 (MIA3) gene regulates plaque stability in coronary artery atherosclerosis. Understanding MIA3

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Coronary artery disease (CAD) fatalities are often linked to atherosclerosis.
  • Melanoma inhibitory activity protein-3 (MIA3) is a key regulator of plaque stability in coronary artery atherosclerosis.

Purpose of the Study:

  • To provide a comprehensive review of the MIA3 gene's role in cellular processes and diseases.
  • To elucidate MIA3's function in the pathogenesis of CAD and other collagen-related disorders.
  • To explore therapeutic strategies targeting the MIA3 signaling pathway.

Main Methods:

  • Literature review of MIA3 gene function, signaling, and therapeutic targets.
  • Analysis of MIA3's role in vesicle transport from the endoplasmic reticulum.
  • Examination of MIA3's involvement in cellular signaling pathways, including COPII complex formation.

Main Results:

  • MIA3 facilitates vesicle budding from the endoplasmic reticulum for apolipoprotein and collagen transport.
  • MIA3 plays a role in the pathogenesis of CAD and diseases with bone mineralization or collagen defects.
  • MIA3 signaling involves protein interactions crucial for vesicular transport.

Conclusions:

  • MIA3 is a critical gene in cardiovascular health, influencing plaque stability and cellular transport.
  • Targeting MIA3 signaling pathways offers potential therapeutic avenues for CAD and related conditions.
  • Further research into MIA3's multifaceted roles is essential for advancing cardiology.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
307
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
355
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
207
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
313